(Q45146732)

English

Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy

scientific article published in November 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 December 2017

Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy (English)

1 reference

Europe PubMed Central

10 December 2017

cystic fibrosis

0 references

1 reference

based on heuristic

inferred from title

multiple drug resistance

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Burkholderia cepacia

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

1

object named as

Joseph L Kuti

1 reference

Europe PubMed Central

10 December 2017

David P Nicolau

3

object named as

David P Nicolau

1 reference

Europe PubMed Central

10 December 2017

author name string

Kerry M Moss

2

1 reference

Europe PubMed Central

10 December 2017

R Frederic Knauft

4

1 reference

Europe PubMed Central

10 December 2017

language of work or name

0 references

publication date

1 November 2004

1 reference

Europe PubMed Central

10 December 2017

Pharmacotherapy

1 reference

Europe PubMed Central

10 December 2017

24

1 reference

Europe PubMed Central

10 December 2017

11

1 reference

Europe PubMed Central

10 December 2017

1641-1645

1 reference

Europe PubMed Central

10 December 2017

Infection control in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1641.50960

21 January 2018

Pseudomonas cepacia infection in cystic fibrosis: an emerging problem

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1641.50960

21 January 2018

Lung transplantation and the Burkholderia cepacia complex

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1641.50960

21 January 2018

Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1641.50960

21 January 2018

Burkholderia cepacia infections in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1641.50960

21 January 2018

Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1641.50960

21 January 2018

Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1641.50960

21 January 2018

Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1641.50960

21 January 2018

Continuous infusion of ceftazidime in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1641.50960

21 January 2018

Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1641.50960

21 January 2018

Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1641.50960

21 January 2018

Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1641.50960

21 January 2018

Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1641.50960

21 January 2018

Infection withBurkholderia cepaciaComplex Genomovars in Patients with Cystic Fibrosis: Virulent Transmissible Strains of Genomovar III Can ReplaceBurkholderia multivorans

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1641.50960

21 January 2018

Identifiers

10.1592/PHCO.24.16.1641.50960

1 reference

Europe PubMed Central

10 December 2017

1 reference

Europe PubMed Central

10 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45146732&oldid=2144418888"